-
-
-
-
-
-
-
BioXcel Therapeutics (BTAI) Misses Q4 EPS by 58c
-
-
-
-
-
-
-
BioXcel Therapeutics (BTAI) PT Raised to $4 at Mizuho, 'Next Financing Remains Our Focus'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI)
-
-
-
-
-
-
-
BioXcel Therapeutics (BTAI) Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY Phase 3 Trial
-
-
-
-
-
-
-
BioXcel Therapeutics (BTAI) Regains Nasdaq Compliance
-
-
-
-
-
-
-
BioXcel Therapeutics (BTAI) Announces Proposed Public Offering
-
-
-
-
-
-
-
BioXcel Therapeutics (BTAI) Announces Clinical Prioritization and Update on BXCL501
-
456,175 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

